DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184

Lupus

Volumn 24, Issue 6, 2015, Pages 648-649

  Van Vollenhoven, Ronald F ^a   Layton, M ^b   Kahl, L ^b   Schifano, L ^c   Hachulla, E ^d   Machado, D ^e   Staumont Salle D ^d   Patel, J ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b GLAXOSMITHKLINE   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

^d UNIV LILLE   (France)

^e CAICI   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMOXICILLIN; BILIRUBIN; CLAVULANIC ACID; CORTICOSTEROID; GSK 2586184; HYDROXYCHLOROQUINE; JANUS KINASE INHIBITOR; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PLACEBO; PREDNISONE; TOFACITINIB; UNCLASSIFIED DRUG; AZETIDINE DERIVATIVE; GSK2586184; JANUS KINASE 1; PROTEIN KINASE INHIBITOR; TRIAZOLE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL PHARYNGITIS; BILIRUBIN BLOOD LEVEL; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DRESS SYNDROME; DRUG ERUPTION; DRUG FEVER; DRUG MEGADOSE; DRUG WITHDRAWAL; EDEMA; EPIGASTRIC PAIN; FOLLOW UP; HUMAN; LARYNGITIS; LETTER; LIVER FUNCTION; LIVER FUNCTION TEST; PHARYNGITIS; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SIDE EFFECT; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; ADULT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY SYNDROME; DRUG-INDUCED LIVER INJURY; ENZYMOLOGY; FEMALE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AZETIDINES; DRUG HYPERSENSITIVITY SYNDROME; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; JANUS KINASE 1; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIAZOLES;

EID: 84928006897     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203315573347     Document Type: Letter

References (6)

1. Seavey MM, Dobrzanski P. The many faces of Janus kinase. Biochem Pharmacol. 2012 ; 83: 1136-1145
2. Norman P. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 ; 23: 1067-1077
3. Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: A literature review. Am J Med. 2011 ; 124: 588-597
4. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, et al. Guidance for Industry. Drug-induced liver injury: Premarketing clinical evaluation, http://www.fda.gov/downloads/Drugs/.../Guidances/UCM174090.pdf (2009, accessed October 2014).
5. XELJANZ. Highlights of prescribing information, http://labeling.pfizer.com/ShowLabeling.aspx?id=959 (2014, accessed October 2014).
6. US Food and Drug Administration, FDA background materials for new drug application 203214: Tofacitinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had inadequate response to one or more disease modifying anti-rheumatic drugs, http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM302958.pdf (2012, accessed October 2014).